Any current/future capex/capital investment/strategic investment?

Current year capex primarily focused on pharma facility and tool room; no large capex beyond this planned for the current year. (Page 17) Major pharma capex expected to complete between Q2 and Q3 of FY '24. (Page 8) Ramp-up of pharma facility expected over the next 4 to 6 quarters, with full utilization likely by the second half of FY '25. (Page 8) Post-improvement in utilization, future capex plans will depend on how utilization levels improve in other business segments. (Page 17) No incremental tooling capex anticipated for the INR 90 crore incremental orders; these orders are accretive at E

Any current/future new fundraising through debt or equity?

There is no specific mention of any current or planned fundraising through debt or equity in the provided transcript from the Q1 FY24 earnings call. Discussions focused on existing investments, capacity expansions, and business growth rather than new funding rounds. The company has already utilized funds raised in 2021 for enhancing capacities and building new healthcare facilities. No guidance or indication was provided about seeking additional debt or equity financing in the near term.

Future growth expectations in sales/revenue/volumes?

Targeting a 60-70% growth in healthcare revenue for the current financial year, indicating a substantial ramp-up in the pharma segment. Expecting to double overall revenue in the next 3 years, supported by increased capacity and new product launches. Pharma business projected to grow faster than the overall business, leading to margin improvement over a 3-year horizon. Adding capacity to manufacture an additional 20 million pens, with volume ramp-up expected over FY '24 to FY '26. Gradual improvement in utilization levels anticipated: - Current utilization expected around 50-55% fo

Future growth expectations in earnings/operating earnings/profits/EPS?

The company anticipates significant growth, targeting approximately 60% growth in the healthcare (pharma) business for the current financial year (FY '24), with sustainable margin improvements expected as this segment expands. Revenue from the pharma business is expected to double over a three-year horizon (by FY '26/'27) driven by new capacity and increased volume. New business wins, including from longstanding client GE Appliances and home furnishings, are expected to contribute incremental revenue starting Q4 FY '24 and Q1 FY '25. Overall EBITDA margins have shown improvement, with a

Current/ Expected Orderbook/ Pending Orders?

Awarded new business from General Electric (GE Appliances) valued at INR 40 crores per annum; signifies a strong and long-standing relationship since 1995 with growing opportunities. Received business confirmations for 3 new home furnishing products, totaling INR 50 crores per annum, enhancing relationship and utilization. Added 3 new products in the automotive and engineering segments contributing to growth. Incremental business of INR 90 crores expected to flow in from Q4 FY '24 and Q1 FY '25 onwards, accretive at EBITDA level without significant incremental capex. Focus on building new stra

Shaily Engineer.Q1 FY24Consumer Durables

Shaily Engineer. Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,009P/E: 81.3Market Cap: ₹14.5K CrSector: Consumer Durables

Management growth scorecard

Revenue

Category 1

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 1

Targeting a 60-70% growth in healthcare revenue for the current financial year, indicating a substantial ramp-up in the pharma segment.
Expecting to double overall revenue in the next 3 years, supported by increased capacity and new product launches.
Pharma business projected to grow faster than the overall business, leading to margin improvement over a 3-year horizon.
Adding capacity to manufacture an additional 20 million pens, with volume ramp-up expected over FY '24 to FY '26.
Gradual improvement in utilization levels anticipated:
- Current utilization expected around 50-55% for FY '24, with gradual improvement over the year.
- Full utilization of new pharma facilities likely by second half of FY '25.
New orders and products (e.g., GE Appliances, home furnishing) to contribute to growth starting Q4 FY '24 and FY '25.
UK subsidiary foresees 2-3x revenue growth in the current financial year.

Margin guidance

Category 3

The company anticipates significant growth, targeting approximately 60% growth in the healthcare (pharma) business for the current financial year (FY '24), with sustainable margin improvements expected as this segment expands.
Revenue from the pharma business is expected to double over a three-year horizon (by FY '26/'27) driven by new capacity and increased volume.
New business wins, including from longstanding client GE Appliances and home furnishings, are expected to contribute incremental revenue starting Q4 FY '24 and Q1 FY '25.
Overall EBITDA margins have shown improvement, with a 290 bps increase in Q1 FY '24, and further margin enhancement is expected over a 3-year perspective as pharma business grows.
Utilization levels are projected to improve gradually; around 50-55% utilization expected in FY '24 with further increases in FY '25, supporting improved profitability.
Earnings growth is guided by doubling revenues in key segments and improved operational efficiencies rather than per-ton gross profit targets.

See what Shaily Engineer. management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no specific mention of any current or planned fundraising through debt or equity in the provided transcript from the Q1 FY24 earnings call.
Discussions focused on existing investments, capacity expansions, and business growth rather than new funding rounds.
The company has already utilized funds raised in 2021 for enhancing capacities and building new healthcare facilities.
No guidance or indication was provided about seeking additional debt or equity financing in the near term.

Order book

Awarded new business from General Electric (GE Appliances) valued at INR 40 crores per annum; signifies a strong and long-standing relationship since 1995 with growing opportunities.
Received business confirmations for 3 new home furnishing products, totaling INR 50 crores per annum, enhancing relationship and utilization.
Added 3 new products in the automotive and engineering segments contributing to growth.
Incremental business of INR 90 crores expected to flow in from Q4 FY '24 and Q1 FY '25 onwards, accretive at EBITDA level without significant incremental capex.
Focus on building new strategic businesses in healthcare, consumer electronics, and industrial applications, with some projects in early stages.
The company refrains from giving precise utilization or revenue guidance for orders but anticipates gradual growth and ramp-up over 18 to 30 months horizon.

See what Shaily Engineer. management said on order book — free account, 30 seconds.

Capex plans

Yes

Current year capex primarily focused on pharma facility and tool room; no large capex beyond this planned for the current year. (Page 17)
Major pharma capex expected to complete between Q2 and Q3 of FY '24. (Page 8)
Ramp-up of pharma facility expected over the next 4 to 6 quarters, with full utilization likely by the second half of FY '25. (Page 8)
Post-improvement in utilization, future capex plans will depend on how utilization levels improve in other business segments. (Page 17)
No incremental tooling capex anticipated for the INR 90 crore incremental orders; these orders are accretive at EBITDA and ROCE levels. (Page 15)
Pharma investments made recently are aimed at accelerating faster revenue growth with increased IP contribution. (Pages 3, 8)

Track Shaily Engineer. — get its next earnings analysis in your feed

How does Shaily Engineer. rank vs peers in Consumer Durables?

Pro feature

ThisShaily Engineer.

Rev 1Mar 3

See where Shaily Engineer. sits in Consumer DurablesSee which companies these are, and every other name in the sector.Open rankings

How does Shaily Engineer. rank in Consumer Durables?

Compare Shaily Engineer. against every Consumer Durables company (Q1 FY24) on revenue, margins and earnings-call signals.

View Consumer Durables leaderboard →

What Shaily Engineer.'s management said in earlier quarters

Others in Consumer Durables this season

Khadim India Ltd (Q1 FY27)
Revenue from Operations for Q1 FY27 stood at ₹778.4 Mn, down by -18.7% YoY (Page 17, 15). Key investor presentation takeaways from Khadim India Ltd's Q1 FY27 in
Duroply Industries Ltd (Q1 FY27)
Year-on-year (YoY) revenue growth: 6.49% (Q1 FY27 vs Q1 FY26) . Key investor presentation takeaways from Duroply Industries Ltd's Q1 FY27 investor presentation
Deepa Jewellers Ltd (Q1 FY27)
Q1-FY27 Revenue from Operations: INR 4,311 Mn, up 39.0% YoY from INR 3,101 Mn in Q1-FY26 (Page 13, 11) . Key investor presentation takeaways from Deepa Jeweller
Priority Jewels Ltd (Q1 FY27)
Revenue from Operations for 3 months ended June 30, 2026 (3M27): ₹1,250 million (page 18). Key investor presentation takeaways from Priority Jewels Ltd's Q1 FY2

Compare:vs Titan Company Ltd vs Asian Paints vs LG Electronics

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →